COVID-19 testing

COVID-19 Now Endemic WHO Reports; What Does it Mean for Testing? Kalorama Information Has Answers

Retrieved on: 
Tuesday, May 9, 2023
Diagnosis, COVID-19 testing, Public, COVID-19, Immunoassay, COVID, IVD, WHO, News, Test market, World Health Organization, Vaccine, Pharmaceutical industry

ARLINGTON, Va., May 9, 2023 /PRNewswire-PRWeb/ -- Three years and more than seven million casualties later, the COVID-19 pandemic is officially no longer a global health emergency, according to a recent statement by the World Health Organization (WHO). Dr. Tedros Adhanom Ghebreyesus, director general of WHO, announced COVID-19's endemic designation in early May, though the decision had been carefully considered for quite some time prior to becoming official.

Key Points: 
  • It is now up to individual countries to determine how to effectively manage COVID in a way that each deems best.
  • This includes maintaining and strengthening commitments to IVD tests targeting COVID-19 specifically," says Bruce Carlson, vice-president and publisher of Kalorama Information.
  • Kalorama Information estimates that the global COVID-19 IVD market reached $29.6 billion in 2022, consisting of immunoassay and molecular testing.
  • For more information or to purchase the market research report "COVID-19 Testing Markets, 2023," visit: https://kaloramainformation.com/product/covid-19-testing-market-update-2... .

Curative Appoints New Chief Operating Officer

Retrieved on: 
Tuesday, May 9, 2023
Professional Services, Health, Insurance, Other Health, Health Insurance, Managed Care, General Health, COVID-19, Prescription, COVID-19 testing, Acquisition, Anthem, Growth, Management, Health insurance, Amerigroup, Curative

Curative Insurance Company , a pioneering provider of a cutting-edge, no copay, no deductible health plan, is pleased to announce the appointment of Patrick Sturdivant to the role of Chief Operating Officer (COO).

Key Points: 
  • Curative Insurance Company , a pioneering provider of a cutting-edge, no copay, no deductible health plan, is pleased to announce the appointment of Patrick Sturdivant to the role of Chief Operating Officer (COO).
  • “Curative is excited to bring Patrick on board as our new COO, as he is truly an innovative leader in the health care and insurance industry,” said Fred Turner, CEO and co-founder of Curative.
  • The Curative health plan is now available to employers throughout Texas and their employees nationally, with broad national network coverage and access to over 1 million providers nationwide.
  • The Curative plan will soon be available to employers in other states across the country.

Fulgent Reports First Quarter 2023 Financial Results

Retrieved on: 
Friday, May 5, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Genetics, Table, NGS, COVID-19, American Society of Clinical Oncology, Pathology, GAAP, COVID-19 testing, EBITDA, Acquisition, Investment, Cancer, Battle of Saint-Fulgent, Depreciation, Society, Pharmaceutical industry, Bank, Beauty salon

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2023.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2023.
  • Non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables.
  • Our cash position continues to afford us the flexibility to be opportunistic and strategic in building a sustainable business for the long-term.”
    For the second quarter of 2023, Fulgent expects:
    For the full year 2023, Fulgent now expects:
    Fulgent will host a conference call for the investment community today at 8:30 AM ET (5:30 AM PT) to discuss its first quarter 2023 results.
  • Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent may not be comparable to similarly titled metrics reported by other companies.

AmerisourceBergen Announces Pharmacy Telehealth Partnership with SteadyMD

Retrieved on: 
Thursday, May 4, 2023
Health, Infectious Diseases, Telemedicine, Virtual Medicine, Health Technology, Managed Care, General Health, Pharmaceutical, Infection, Partnership, Senior, Pharmacy, COVID-19, COVID-19 testing, Thought, Organization, Good Neighbor Pharmacy, Pharmacist, Patient, SVP, Nursing, Pharmaceutical industry, AmerisourceBergen, Test

AmerisourceBergen (AB), a global healthcare company, has announced a strategic partnership with SteadyMD, a B2B telehealth infrastructure provider that powers high-quality telehealth patient experiences for leaders and innovators in healthcare.

Key Points: 
  • AmerisourceBergen (AB), a global healthcare company, has announced a strategic partnership with SteadyMD, a B2B telehealth infrastructure provider that powers high-quality telehealth patient experiences for leaders and innovators in healthcare.
  • With its telehealth solution, AmerisourceBergen is evaluating the long-term viability of the Test to Treat model for use cases, beyond COVID-19, to improve access to treatment.
  • "We're excited to embark on a commercial partnership with AmerisourceBergen and welcome the company to our supportive family of investors," said Guy Friedman, CEO of SteadyMD.
  • In addition to the commercial partnership, AmerisourceBergen has also made an investment in SteadyMD through its venture fund AB Health Ventures.

OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Wednesday, May 3, 2023
Operating cost, Intellectual property, Pfizer, International, EU, GeneDx, Growth hormone, Center for Drug Evaluation and Research, COVID-19, Health, Research, COVID-19 testing, Modex, Sale, OPKO Health, PIN, Cervical cancer, Patient, Laboratory, Roche, United Kingdom, Growth, FDA, Therapy, PCR, Video game, Pharmaceutical industry, Sanofi, Merck

MIAMI, May 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023.

Key Points: 
  • MIAMI, May 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023.
  • Operating income was $19.0 million in the first quarter of 2023, compared with an operating loss of $18.1 million in the first quarter of 2022.
  • Operating loss for the first quarter of 2023 decreased $41.8 million to $30.6 million from $72.4 million for the 2022 quarter.
  • OPKO’s senior management will provide a business update, discuss first quarter financial results, provide financial guidance and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. Eastern time.

Pacific Mobile Structures Receives 'Best in Show' and Two First Place Awards at the 2023 World of Modular Annual Convention and Tradeshow

Retrieved on: 
Wednesday, May 3, 2023
Education, Trade fair, Impact of the COVID-19 pandemic on Native American tribes and tribal communities, COVID-19, Modularity, COVID-19 testing, HVAC, Suquamish, Architect, Diagnosis, San Diego International Airport, MBI, Video game, Prefabrication, Construction

CHEHALIS, Wash., May 3, 2023 /PRNewswire-PRWeb/ -- Pacific Mobile Structures is thrilled to announce that their project for the San Diego Airport and the Suquamish Tribal Health Clinic project were awarded first place in their respective categories of 'Relocatable Modular Office Over 10,000 square-feet,' and 'Permanent Modular Healthcare Under 10,000 square-feet.' Additionally, the San Diego Airport project received 'Best of Show Relocatable Building.'

Key Points: 
  • Pacific Mobile Structures received two first place awards and the coveted 'Best of Show Relocatable Building' award at the 2023 World of Modular Annual Convention and Tradeshow.
  • The Modular Building Institute (MBI) is the international non-profit trade association serving the modular construction industry.
  • They really spent the time vetting Pacific Mobile on this job and the result was a beautiful modular health clinic.
  • The building truly fits the surroundings and accents the area," said Patrick Allen, Pacific Mobile Structures Sales Representative.

ProPhase Labs CEO Ted Karkus Named One of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023

Retrieved on: 
Friday, April 28, 2023
Therapy, Coronavirus, COVID-19, Genomics, COVID-19 testing, Nebula Genomics, Inc., Growth, Prophase, Pharmaceutical industry

Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, is pleased to announce that Ted Karkus, CEO, has been named one of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023.

Key Points: 
  • Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, is pleased to announce that Ted Karkus, CEO, has been named one of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023.
  • The annual listing represents dynamic healthcare leaders redefining the world with their innovative products and leadership.
  • Mr. Karkus was recognized by Inc Magazine for his visionary leadership in the healthcare industry, as well as his dedication to driving innovation and improving patient outcomes.
  • Mr. Karkus commented, “I am honored to be recognized by Inc Magazine as one of the 10 Most Innovative Healthcare Leaders to Watch for 2023.

Thermo Fisher Scientific Reports First Quarter 2023 Results

Retrieved on: 
Wednesday, April 26, 2023
Science, Other Science, Research, San Francisco, Partnership, Food, University, Applied Biosystems, Drink, Table, University of California, San Francisco, COVID-19, TMO, GAAP, Thermo Fisher Scientific, Binding site, COVID-19 testing, Element, Acquisition, Soil, UCSF, CGMP, Water, Invitrogen, EPS, PPI, Mindful Scientific Inc., NYSE, PCR, Management, Video game, Pharmaceutical industry

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023.
  • GAAP operating income for the first quarter of 2023 was $1.56 billion, compared with $2.82 billion in the year-ago quarter.
  • Adjusted operating income for the first quarter of 2023 was $2.33 billion, compared with $3.45 billion in the year-ago quarter.
  • Thermo Fisher Scientific will hold its earnings conference call today, April 26, 2023, at 8:30 a.m. Eastern Time.

Labcorp Announces 2023 First Quarter Results

Retrieved on: 
Tuesday, April 25, 2023
Capital expenditure, COVID-19 testing, Corporate social responsibility, Launch pad, COVID-19, Drug, LH, COVID, FSP, Public expenditure, Acquisition, Laboratory, Corporation, Capital, Council for the Central Laboratory of the Research Councils, Growth, Weather, EPS, NHP, Health, NYSE, PCR, Ascension, Management, Pharmaceutical industry, Video game, Public utility, Labcorp

BURLINGTON, N.C., April 25, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2023, and updated full-year guidance.

Key Points: 
  • BURLINGTON, N.C., April 25, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2023, and updated full-year guidance.
  • In the first quarter, Labcorp executed against its strategic plan to position the business for both short- and long-term growth.
  • Revenue for the quarter was $3.78 billion, a decrease of (3.1%) from $3.90 billion in the first quarter of 2022.
  • Labcorp is updating 2023 full year guidance to reflect its first quarter performance and full year outlook.

Curative Announces Spin-Off of Sensible Diagnostics with their Game-Changing 10-Minute Point-Of-Care PCR Testing Platform

Retrieved on: 
Monday, April 24, 2023
Science, Other Science, Medical Supplies, Health, COVID-19, Medical Devices, Infectious Diseases, Clinical Trials, Inc., STI, MBA, Doctor of Philosophy, COVID-19 testing, Patient, Point-of-care testing, Series, Knowledge, Sensible, PCR, Mistake, Medical device, Pharmaceutical industry, Curative

Curative Inc., a leading health services company that recently launched a new health plan out of Texas, announces the spin-off of Sensible Diagnostics, whose aim is to commercialize their groundbreaking point-of-care PCR testing platform.

Key Points: 
  • Curative Inc., a leading health services company that recently launched a new health plan out of Texas, announces the spin-off of Sensible Diagnostics, whose aim is to commercialize their groundbreaking point-of-care PCR testing platform.
  • “We are excited to be rolling out Sensible Diagnostics to bring a revolutionary, efficient PCR 10-minute desktop testing platform to the masses,” said Fred Turner, CEO and co-founder of Curative.
  • With prices that are competitive with lateral flow antigen testing, Sensible Diagnostics’ platform is setting out to make lateral flow immunoassay testing a thing of the past.
  • Sensible Diagnostics’ and its point-of-care testing platform came to fruition out of Curative’s COVID-19 testing business.